Axsome Therapeutics: A Company With Booming Catalysts And A Remarkable Innovation In Treating DepressionSeeking Alpha • 12/24/19
Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 12/23/19
Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common StockGlobeNewsWire • 12/19/19
Axsome Therapeutics News: AXSM Stock Rockets 76% on Depressive Disorder Drug ResultsInvestorPlace • 12/16/19
High Flying Biotech Axsome Skyrockets On Positive Late-Stage Results For Depression DrugBenzinga • 12/16/19
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive DisorderGlobeNewsWire • 12/16/19
A Last-Minute Look At AXS-05 Revealed That Axsome Therapeutics May Have A Better Risk/Reward Profile In Its Major Depressive Disorder PipelineSeeking Alpha • 12/09/19